Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Issuance of warrants

Faron Pharmaceuticals OyAnnouncement

30/04/2026 07:02

Faron Pharmaceuticals Ltd | Company announcement | April 30, 2026 at 09:00:00
EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company, announces that it has issued to IPF
Fund II SCA, SICAV-FIAR (“IPF”) 321,523 additional warrants over ordinary
shares in the Company (“Warrants”), following the the amortisation of the
first and second tranche convertible bonds to Heights Capital Management,
Inc.at EUR 0.4516 announced on 13 April 2026.

The subscription price of all of the Warrants held by IPF is reset to EUR
0.4516 (“Subscription Price”). As described in the Warrant Terms and
Conditions announcement of 8 April 2024, in the event of any future share
issue at a price lower than the Subscription Price, the Subscription Price of
the Warrants will be adjusted to that lower subsequent price.

Following this issues, IPF will have an interest in 3,641,467 Warrants,
representing approximately 1.83% of the issued share capital in the Company.
Each Warrant entitles its holder to subscribe for one new share in the
Company. The Warrants may be exercised for a period of seven years from the
original date of issue.

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     |         kare.laukkanen@irpartners.fi |
| Kare Laukkanen                      |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   |                     +1 847 791-8085  |
| (Media)                             |        alyssa.paldo@finnpartners.com |
| Alyssa Paldo                        |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        |                 +44 (0) 207 213 0880 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    |                  +358 (0)40 555 4727 |
| (Certified Adviser on Nasdaq First  |                  +358 (0)50 553 8990 |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune
system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on
macrophages, bexmarilimab alters the tumor microenvironment, reprogramming
macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1)
one, upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The company’s lead asset, bexmarilimab, is a novel
macrophage-guiding immunotherapy being investigated in multiple oncology
settings. Further information is available at www.faron.com
(http://www.faron.com/)